Logan Coy Related postsA Phase 1, Open-Label, Multicenter, Dose Escalation Study of SGR-1505 as Monotherapy in Mature B-Cell MalignanciesSeptember 11, 2026A Phase 1/2 Open-Label, Dose-Escalation Study of Quaratusugene Ozeplasmid in Combination with Osimertinib in Advanced, EGFR-Mutant, Metastatic NSCLC that Progressed after OsimertinibSeptember 11, 2026A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin LymphomaSeptember 11, 2026 Previous postAn Open-Label, Phase 2b Global Multicenter Cohort Trial of Zipalertinib in Locally Advanced or Metastatic NSCLC with Exon 20 Insertion and Uncommon/Single or Compound EGFR MutationsNext postEfficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician’s Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCLC (VIRO-25)
